Patent ID: 8399442
Filing Date: 2013-03-19
Classification: A61K,A61P,C07D

Abstract:
1. A method for the treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK, C-abl, PDK1, Chk, FGFR, Ret, Eph, or Src; or B. a cancer in which the cancer cells thereof contain a drug resistant kinase mutation which is: C. a cancer which expresses a mutated molecular target which is a mutated form of BCRabl , c-kit, PDGF, EGF receptor or ErbB2; which method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of the formula: or a salt, solvate, tautomer, or N-oxide thereof.